| Wang, Xin Shelley |
NCT03908138: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma |
|
|
| Recruiting | 4 | 120 | RoW | RDD, RDD group, VDD, VDD group | Shandong Provincial Hospital | Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety | 12/21 | 12/22 | | |
NCT06398834: Esketamine and Butorphanol for Post-Lobectomy Pain |
|
|
| Completed | 4 | 223 | RoW | Esketamine, S-Ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, L-Ketamine, (-)-Ketamine, Butorphanol, Butorphanol Tartrate, Moradol, Stadol, Torbugesic, Apo-Butorphanol, Dolorex | Second People's Hospital of Hefei City, Tongji Hospital | Esketamine, Pain, Post-thoracotomy Pain Syndrome, Thoracic Diseases | 10/23 | 01/24 | | |
NCT04738955: Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors |
|
|
| Recruiting | 4 | 230 | RoW | Micafungin Sodium | Shandong Provincial Hospital | Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | 01/23 | 10/23 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 |
|
|
| Recruiting | 3 | 2 | RoW | SIB-IMRT, Paclitaxel, Platinum-Based Drug, Involved Field Irradiation (IFI) | Chinese Academy of Medical Sciences | IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer | 08/21 | 12/22 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
NCT03978364: A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC |
|
|
| Recruiting | 3 | 100 | RoW | Azacitidine combined HHT, Azacitidine+HHT, Azacitidine regimen, Azacitidine group | Shandong Provincial Hospital | Myelodysplastic Syndromes,Acute Myeloid Leukemia | 06/22 | 12/22 | | |
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX | Shandong Provincial Hospital | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/24 | | |
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies | Shandong Provincial Hospital | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma | 12/23 | 12/24 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer | 12/25 | 12/25 | | |
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect | 12/25 | 12/25 | | |
NCT05406882: The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis |
|
|
| Recruiting | 2/3 | 176 | RoW | Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules, Probiotics、Glutamine | West China Hospital | Radiation Proctitis, Probiotics, Glutamine, Gut Microbiota, Bifidobacterium | 04/24 | 09/24 | | |
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer |
|
|
| Completed | 2 | 55 | RoW | Radiotherapy, Nimotuzumab, S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm | 12/22 | 06/23 | | |
Rvision-001, NCT04147728: Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Anlotinib, Antiangiogenic agents, Stereotactic Radiosurgery | Peking University Third Hospital, Huashan Hospital, Tianjin Medical University | Stereotactic Body Radiation Therapy | 12/21 | 12/22 | | |
NCT04547452: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC |
|
|
| Recruiting | 2 | 84 | RoW | Stereotactic body radiation therapy, SBRT, Anti-PD-1 antibody drug named Sintilimab | West China Hospital | Stage IV HCC, Immunotherapy, SBRT | 07/22 | 07/23 | | |
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients |
|
|
| Recruiting | 2 | 55 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, AK104 | Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Urothelial Carcinoma | 09/24 | 04/26 | | |
NCT04821765: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel, Cisplatin | Chinese Academy of Medical Sciences | Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy | 09/23 | 09/23 | | |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 186 | RoW | Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene | Locally Advanced Rectal Cancer | 03/24 | 09/29 | | |
NCT06334367: Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT |
|
|
| Not yet recruiting | 2 | 40 | RoW | CD25 treatment, low-dose ATG | Wang Xin | GVHD | 03/26 | 03/26 | | |
| Recruiting | 2 | 90 | RoW | Tislelizumab (BGB-A317) with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 12/26 | 12/27 | | |
NCT06421376: Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy, Surgery | 12/26 | 12/27 | | |
NCT05490485: Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab, cisplatin | Henan Cancer Hospital | Squamous Cell Carcinoma of the Skin | 07/24 | 07/24 | | |
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Chidamide Tablets combined with AK112, AK112 | Shanxi Province Cancer Hospital | Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone | 12/24 | 12/24 | | |
NCT06074484: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, Disitamab Vedotin, AK104, Cadonilimab Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | Muscle Invasive Bladder Carcinoma | 08/24 | 08/25 | | |
NCT06642545: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin, RC48, RC148, Albumin-bound Paclitaxone, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 10/26 | 10/27 | | |
NCT05430737: A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer |
|
|
| Recruiting | 2 | 60 | RoW | stereotactic body radiotherapy | West China Hospital | Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy, Safety | 06/25 | 06/25 | | |
NCT06123455: Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen | Tang-Du Hospital | Gastric Cancer | 07/25 | 07/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
NCT04278287: Chemoradiotherapy in Unresectable Esophageal Cancer |
|
|
| Recruiting | 1/2 | 105 | RoW | Radiotherapy, Albumin-Bound Paclitaxel, Nab-Paclitaxel, Cisplatin, platinum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm | 12/25 | 12/26 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 10/23 | 12/23 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
NCT06344936: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 28 | RoW | HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules | Shandong Suncadia Medicine Co., Ltd. | Chronic Kidney Disease(CKD) | 07/24 | 07/24 | | |
NCT02988921: MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy |
|
|
| Recruiting | N/A | 300 | RoW | MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer | 01/25 | 12/26 | | |
NCT03247764: A Registration Study on Depression in Patients With Epilepsy |
|
|
| Recruiting | N/A | 320 | RoW | | Shanghai Zhongshan Hospital | Epilepsy, Depression | 12/21 | 01/22 | | |
NCT03902041: The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT |
|
|
| Not yet recruiting | N/A | 160 | RoW | Eltrombopag | Shandong Provincial Hospital | Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag | 04/22 | 10/22 | | |
| Recruiting | N/A | 300 | RoW | Paclitaxel DCB | Beijing Hospital | Coronary Disease | 01/23 | 07/23 | | |
NCT06347965: Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy |
|
|
| Completed | N/A | 104 | RoW | Low load blood flow restriction training, Progressive resistance training group | Xin Wang | Sarcopenia, Lung Neoplasms | 11/23 | 02/24 | | |
NCT06391788: Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy |
|
|
| Recruiting | N/A | 132 | RoW | thoracoscopic Morrow surgery, modified Morrow surgery | China National Center for Cardiovascular Diseases | Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery | 02/25 | 03/25 | | |
NCT04502628: Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT |
|
|
| Recruiting | N/A | 150 | RoW | Hyperbaric oxygen therapy | Shandong Provincial Hospital | Stem Cell Transplant Complications | 07/23 | 12/24 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT04664439: Follow-up With CT-FFR in CHD Patients After DCB |
|
|
| Recruiting | N/A | 92 | RoW | CT-FFR | Beijing Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College | Coronary; Ischemic | 12/23 | 06/24 | | |
NCT05723731: Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation |
|
|
| Terminated | N/A | 106 | RoW | taVNS, Laxative Agent | Air Force Military Medical University, China | Chronic Constipation | 07/23 | 09/23 | | |
NCT05718778: Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma |
|
|
| Recruiting | N/A | 31 | RoW | Piamprimab (AK105), radiotherapy | Henan Cancer Hospital | Soft Tissue Sarcoma | 03/24 | 03/24 | | |
CLL2023, NCT05920668: Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Orelabrutinib | Wang Xin | CLL/SLL | 07/24 | 07/25 | | |
NCT06128252: Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | N/A | 96 | RoW | Taurine, Serplulimab, XELOX regimen, Placebo | Tang-Du Hospital | Gastric Cancer | 06/26 | 06/26 | | |
NCT05934864: Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) |
|
|
| Recruiting | N/A | 1000 | RoW | 84-gene penal | Ruijin Hospital, West China Hospital, Shandong Provincial Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital | Peripheral T Cell Lymphoma | 06/25 | 06/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT04874493: Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer |
|
|
| Active, not recruiting | N/A | 77 | US | Electronic Health Record Review, Questionnaire Administration | M.D. Anderson Cancer Center | Oropharyngeal Carcinoma | 02/27 | 02/27 | | |
NCT00505245: New Assessment System in Measuring Symptom Distress in Cancer Patients |
|
|
| Recruiting | N/A | 6500 | US | Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH) | Caregiver, Health Care Provider, Malignant Neoplasm, Physician | 04/31 | 04/31 | | |
NCT05628480: Multi-omics Analyses Reveal Microbiota-gut-brain Axis in ICU Patients With Post-cardiac Surgery Delirium |
|
|
| Completed | N/A | 60 | RoW | | China National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences | Postoperative Delirium, Cardiac Disease, Gastrointestinal Microbiome | 10/23 | 10/23 | | |
| Fan, Jia |
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) |
|
|
| Not yet recruiting | 4 | 600 | NA | Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Unresectable Hepatocellular Carcinoma | 09/25 | 01/27 | | |
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 490 | RoW | IBI310, Sintilimab, Sorafenib | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 360 | RoW | TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 07/24 | 07/26 | | |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/22 | 12/24 | | |
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC |
|
|
| Active, not recruiting | 2 | 45 | RoW | GP+PD-1+Tight | Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University | Biliary Tract Carcinoma | 01/23 | 12/24 | | |
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer |
|
|
| Completed | 2 | 8 | RoW | TST001 | Shanghai Zhongshan Hospital, Transcenta Holding Limited | Biliary Tract Neoplasms | 05/23 | 05/23 | | |
ZSAB-TransGOLP, NCT05156788: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | PD-1+Lenvatinib+GEMOX | Shanghai Zhongshan Hospital | Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib | 07/23 | 10/25 | | |
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima | Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital | Advanced Biliary Tract Carcinoma | 12/24 | 12/25 | | |
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. |
|
|
| Recruiting | 2 | 117 | RoW | HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 02/27 | 02/27 | | |
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. |
|
|
| Not yet recruiting | 2 | 49 | RoW | HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy | Shanghai Zhongshan Hospital | Biliary Tract Cancer | 12/26 | 06/27 | | |
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 55 | RoW | Anlotinib and TQB2450 | Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 10/25 | 12/25 | | |
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma |
|
|
| Terminated | 1/2 | 40 | RoW | Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 06/28 | 06/28 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT06584071: A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC |
|
|
| Not yet recruiting | 1/2 | 140 | NA | PM8002, PM1009, atezolizumab, bevacizumab | Biotheus Inc. | HCC, Liver Cancer | 10/26 | 12/27 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
ZSAB-Calm, NCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody |
|
|
| Recruiting | 1/2 | 96 | RoW | cardonilizumab, PD1 and CTLA-4 bispecific antibody, LM-302, ClAUDIN 18.2-ADC | Shanghai Zhongshan Hospital | Biliary Tract Cancer, Candonilimab, Claudin 18.2 | 08/25 | 08/26 | | |
NCT05701553: Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 20 | RoW | Anti-PD-1/PD-L1, S-Adenosyl-Methionine, SAM | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 108 | RoW | IMM27M, IMM2510 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Advanced Solid Tumors, HCC | 01/26 | 01/26 | | |
NCT06757881: IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1 | 18 | RoW | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） | Shanghai Zhongshan Hospital | HCC | 04/25 | 12/27 | | |
NCT03045731: An US Mathematical Model in Predicting Renal Transplant Rejection |
|
|
| Recruiting | N/A | 180 | RoW | | Shanghai Zhongshan Hospital | Kidney Transplantation | 09/22 | 12/22 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
| xu, jianmin |
NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer |
|
|
| Recruiting | 3 | 78 | RoW | VIC, Bevacizumab Plus Chemotherapy | Fudan University | Colorectal Cancer | 08/22 | 12/22 | | |
PIDUC, NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis |
|
|
| Not yet recruiting | 3 | 80 | RoW | Trans arterial chemoembolization with Irinotecan Drug-eluting Beads, Irinotecan Drug-eluting Beads | Fudan University | Colorectal Cancer, Liver Metastases | 12/22 | 06/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM |
|
|
| Not yet recruiting | 3 | 250 | RoW | mFOLFOX6 + Cetuximab, mFOLFOX 6 | Fudan University | Colorectal Cancer, Liver Metastases | 07/26 | 07/26 | | |
